文献速递外周动脉疾病

糖尿病对下肢血管内血运重建后主要肢体结局的影响

Major Limb Outcomes Following Lower Extremity Endovascular Revascularization in Patients With and Without Diabetes Mellitus.
PubMed 文献 · J Endovasc Ther · 2017-04-25

基于XLPAD注册研究1906例患者,分析糖尿病对下肢PAD血管内治疗后12个月结局的影响。校正混杂因素后,糖尿病与靶肢体大截肢风险(HR 5.02)和全因死亡风险(HR 4.64)显著升高相关,在CLI亚组中尤为突出。

要点

  • 糖尿病是下肢血管内治疗后12个月大截肢和全因死亡的独立危险因素。
  • CLI患者中糖尿病相关风险更高,大截肢HR 3.48虽未达显著(p=0.056)。
  • 糖尿病与再次血运重建率相似,风险主要集中在截肢和死亡。

核心结论

  • 糖尿病增加症状性PAD患者血管内血运重建后12个月大截肢和全因死亡风险。
  • CLI患者中上述风险尤其显著增高。

研究设计与样本

  • 观察性XLPAD注册研究(NCT01904851),纳入2005年1月至2015年10月1906例连续患者(平均年龄66岁,1469例男性),共2426条肢体接受索引血管内手术。
  • 采用Kaplan-Meier分析和校正Cox比例风险模型进行时间-事件分析,覆盖全样本及CLI和跛行亚组。

主要发现

  • 糖尿病患者合并症更多、CLI比例更高、严重钙化病变更多、多血管病变更多、膝下流出道血管更少(均p<0.05)。
  • 校正混杂因素后,糖尿病患者靶肢体大截肢风险显著高于非糖尿病患者(HR 5.02,95%CI 1.44-17.56,p=0.011)。
  • 再次血运重建率在糖尿病与非糖尿病之间相似。
  • CLI亚组中糖尿病与12个月大截肢风险增加相关但未达统计学显著(HR 3.48,95%CI 0.97-12.51,p=0.056)。
  • 全样本中糖尿病与12个月全因死亡风险增加相关(HR 4.64,95%CI 2.01-10.70,p<0.001),CLI亚组HR 14.15(95%CI 3.16-63.32,p<0.001),跛行亚组无显著关联(HR 1.42,95%CI 0.45-4.54,p=0.552)。

临床怎么用

  • 对接受下肢血管内血运重建的糖尿病患者应加强术后监测,尤其关注大截肢和死亡风险。
  • 合并CLI的糖尿病患者术后风险最高,需强化多学科管理和随访。

局限性

  • 观察性注册研究,可能存在未测量混杂因素。
  • CLI亚组中大截肢风险未达统计学显著,需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To determine whether diabetes mellitus has an independent impact on major limb outcomes at 1 year after endovascular treatment of lower extremity peripheral artery disease (PAD). METHODS: The study involved 1906 consecutive patients (mean age 66 years; 1469 men) enrolled in the observational Excellence in Peripheral Artery Disease (XLPAD) registry ( ClinicalTrials.gov identifier NCT01904851) between January 2005 and October 2015 after undergoing index endovascular procedures in 2426 limbs for arterial occlusive disease. Patient outcomes included 12-month target limb amputation (above ankle) and target limb revascularization as well as all-cause death. Kaplan-Meier analysis and adjusted Cox proportional hazard models were used for time-to-event analysis of outcomes for the entire study sample as well as for the critical limb ischemia (CLI) and claudication subgroups. Results of the Cox regression models are reported as the hazard ratio (HR) and 95% confidence interval (CI). RESULTS: Diabetics undergoing endovascular procedures had higher rates of comorbid conditions (p<0.001), CLI (p<0.001), heavily calcified lesions (p=0.002), multivessel disease (p=0.030), and fewer infrapopliteal runoff vessels (p<0.001). Regression analysis after adjusting for confounders revealed significantly higher target limb major amputation in diabetics compared with nondiabetics (HR 5.02, 95% CI 1.44 to 17.56, p=0.011). However, repeat revascularization rates were similar. When considering CLI and claudication subgroups, diabetes was associated with a nonsignificant increased risk of 12-month major amputation only for patients presenting with CLI (HR 3.48, 95% CI 0.97 to 12.51, p=0.056). Diabetes was also associated with an increased risk of 12-month all-cause mortality in the overall study sample (HR 4.64, 95% CI 2.01 to 10.70, p<0.001) and in the CLI subgroup (HR 14.15, 95% CI 3.16 to 63.32, p<0.001) but not in the claudication subgroup (HR 1.42, 95% CI 0.45 to 4.54, p=0.552). CONCLUSION: Diabetes increases the risk of major amputation and all-cause death at 12 months following endovascular revascularization in patients with symptomatic PAD. These risks are especially heightened in patients presenting with CLI.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. Shammas AN, Jeon-Slaughter H, Tsai S, et al. Major Limb Outcomes Following Lower Extremity Endovascular Revascularization in Patients With and Without Diabetes Mellitus. J Endovasc Ther. 2017. PMID: 28440113. doi:10.1177/1526602817705135

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。